A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

NCT07199465

Status	RECRUITING
Phase	Phase 1
Sponsor	Merck Sharp & Dohme LLC
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (7)

- Is a recipient of a primary or secondary allograft kidney
- Is at least 4 weeks posttransplant and not more than 52 weeks posttransplant at the time of enrollment (Day 1) and is being managed per local standard of care
- Has stable kidney function posttransplant
- Has undetectable CMV deoxyribonucleic acid (DNA) from a plasma or whole blood sample collected within 14 days prior to enrollment
- Must be able to take (as assessed by the investigator) letermovir tablets or oral pellets by mouth, or via gastrostomy or nasogastric tube (oral pellets only)

... and 2 more (see full listing online)

Exclusion (8)

- Has CMV disease or suspected CMV disease between screening and enrollment
- Is on dialysis or plasmapheresis at the time of enrollment
- Has evidence of CMV viremia at any time from screening until the time of enrollment
- Has Child-Pugh B or C hepatic insufficiency within 14 days before enrollment
- Is a multi-organ transplant recipient (e.g., kidney-pancreas)

... and 3 more (see full listing online)

Locations (11 total)

UCLA Clinical & Translational Research Center (CTRC) (Site 0006), Los Angeles, California, United States
Lucile Packard Children's Hospital (Site 0001), Palo Alto, California, United States
University of California Davis Health (Site 0023), Sacramento, California, United States
... and 8 more locations